Literature DB >> 9549809

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group.

D Osoba1, B Zee.   

Abstract

The approach of the National Cancer Institute of Canada Clinical Trials Group to measuring compliance, that is, completion rates, for health-related quality of life questionnaires is presented. Completion rates can be measured at the institutional, patient, questionnaire and item levels for baseline, on-treatment and off-treatment follow-up study periods. Time windows are defined for each expected completion time. In seven completed clinical trials, completion rates were high with more than 93 per cent of patients completing questionnaires in the specified time windows at baseline and while on-treatment. The rate while on off-treatment follow-up is still acceptable at 85 per cent. The proportions of analysable questionnaires were 97.6 per cent, 82.0 per cent and 77.0 per cent respectively, at the three study periods. Item completion rates within questionnaires were high at 95.5 per cent or more. The variables most likely to influence baseline and on-treatment questionnaire completion rates were breast cancer, ovarian cancer, metastases and study centre size.

Entities:  

Mesh:

Year:  1998        PMID: 9549809     DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<603::aid-sim807>3.0.co;2-d

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer.

Authors:  Zeinab Hamidou; Tienhan S Dabakuyo; Mariette Mercier; Jean Fraisse; Sylvain Causeret; Hervé Tixier; Marie-Martine Padeano; Catherine Loustalot; Jean Cuisenier; Jean-Marc Sauzedde; Marc Smail; Jean-Philibert Combier; Patrick Chevillote; Christian Rosburger; Patrick Arveux; Franck Bonnetain
Journal:  Oncologist       Date:  2011-09-23

2.  Comparison of health-related quality of life questionnaires in ambulatory oncology.

Authors:  Mary E Cooley; Ruth McCorkle; George J Knafl; Joan Rimar; Margaret J Barbieri; Marianne Davies; John Murren
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

3.  Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992).

Authors:  Pamela J Atherton; Kelli N Burger; Levi D Pederson; Suneetha Kaggal; Jeff A Sloan
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

4.  Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Authors:  Pablo E Serrano; Joseph M Herman; Kent A Griffith; Mark M Zalupski; Edward J Kim; Tanios S Bekaii-Saab; Edgar Ben-Josef; Laura A Dawson; Jolie Ringash; Alice C Wei
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-04       Impact factor: 7.038

5.  Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers.

Authors:  Melanie Calvert; Derek Kyte; Helen Duffy; Adrian Gheorghe; Rebecca Mercieca-Bebber; Jonathan Ives; Heather Draper; Michael Brundage; Jane Blazeby; Madeleine King
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

6.  Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.

Authors:  F Mouriaux; V Servois; J J Parienti; T Lesimple; A Thyss; C Dutriaux; E M Neidhart-Berard; N Penel; C Delcambre; L Peyro Saint Paul; A D Pham; N Heutte; S Piperno-Neumann; F Joly
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

7.  Challenges in Acceptance and Compliance in Digital Health Assessments During Pregnancy: Prospective Cohort Study.

Authors:  Katharina Brusniak; Hannah Maria Arndt; Manuel Feisst; Kathrin Haßdenteufel; Lina Maria Matthies; Thomas Maximilian Deutsch; Hannes Hudalla; Harald Abele; Markus Wallwiener; Stephanie Wallwiener
Journal:  JMIR Mhealth Uhealth       Date:  2020-10-14       Impact factor: 4.773

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.